Pricing Log in Create free account
Friday 6 November 2026 Export STTK’s income statement to Excel — free account

Shattuck Labs, Inc.

STTK Healthcare Biotechnology

Shattuck Labs, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.0 million, down 82.5% from fiscal 2024.

Revenue
−10.3%
EPS
+50.0%
Free cash flow
+1.01%

Quarter to June 2026, against a year earlier

4.59 0.10 +2.23%
Market cap
$450.6M
P/E
0.0×
Fwd P/E
−12.4×
Dividend yield
—
F-score
4/9
Altman Z
10.16
Beneish M
n/a
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 0.25
Sold, $m 0.59
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — 1 — — — — —
Sell — — — — — 2 2 1 — — — —
Insider Ownership 33.56%

Capital & Financial Ratios $m

Size
Market Cap 450.63
Revenue ttm 5.61
Net income ttm (52.57)
Free cash flow ttm (41.24)
Net debt Q (208.30)
Valuation
P/E 0.00
Forward P/E (12.40) (negative: loss-making)
Price / sales 106.26 (above 10: high)
Forward P/S Powerpack
Price / FCF 0.00
Price / book 2.82
Financial health
Current ratio Q 27.59 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q —
Growth
Revenue growth Q −10.31% (below 0%: shrinking)
Operating income growth Q −23.96% (below 0%: shrinking)
EPS, this year +23.65% (at or above 15%: strong)
EPS, next year A −5.52% (below 0%: weak)
Revenue, next year A −88.89% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A +3.94%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 69.1×, against a ten-year median of 12.6×; over the ten years it ranged from −61.3× in 2023 to 501× in 2021.
P/S against its own 10 years 63.20%
10-year low 10-year high
P/B against its own 10 years 70.88%
10-year low 10-year high
EV/Sales against its own 10 years 49.49%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 131 73 78 208
Receivables — — — —
Inventory — — — —
Other — — — —
143 79 82 213
2023 2024 2025 Q'26
Payables 2 2 2 4
ST’ Debt — — — —
Other — — — —
11 9 7 8

Compound Annual Growth %

10y 5y 3y
Sales — (36.82%) 15.32%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — (23.27%) (22.38%)

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.14 Actual −0.12

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 −0.15 −0.14 Beat by 0.01
Q4 FY25 −0.12 −0.12 Met by 0.00
Q1 FY26 −0.14 −0.13 Beat by 0.01
Q2 FY26 −0.14 −0.12 Beat by 0.02
Q3 FY26 −0.10 — Reports 5 November 2026

EPS $

Mar Jun Sep Dec Year
’26 (0.13) (0.12) — — —
’25 (0.27) (0.24) (0.14) (0.12) (0.70)
’24 (0.37) (0.42) (0.33) (0.37) (1.49)
’23 (0.49) (0.50) (0.65) (0.41) (2.05)
’22 (0.58) (0.65) (0.58) (0.60) (2.41)
’21 (0.28) (0.56) (0.41) 0.18 (1.07)
’20 (0.86) (0.81) (1.54) (0.31) (2.36)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 — — — — —
’25 — — 1 — 1
’24 1 2 3 0 6
’23 0 0 1 1 2
’22 — 0 0 0 1
’21 2 (4) 2 30 30
’20 3 3 2 1 10
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (13) (10) — — —
’25 (12) (10) (9) (8) (40)
’24 (16) (11) (16) (17) (61)
’23 (26) (19) (17) (19) (81)
’22 (26) (16) (28) (24) (94)
’21 (11) (14) (13) (19) (57)
’20 (10) 2 (11) (14) (34)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (13) (10) — — —
’25 (12) (10) (9) (8) (40)
’24 (16) (11) (16) (17) (61)
’23 (27) (19) (17) (19) (82)
’22 (29) (24) (29) (24) (106)
’21 (14) (17) (14) (21) (65)
’20 (11) 2 (11) (14) (34)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — — 22 10 10 30 1 2 6 1 6 (35.9%) 0 0 0 (50.0%)
Gross margin, % — — 0.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 +100.0 pt
EBT — — (7) (24) (37) (45) (102) (87) (75) (49) (53) +31.0%
EBT margin, % — — (32.92) (242.56) (368.46) (149.83) (15,635.74) (5,268.44) (1,318.13) (4,880.90) 0.00 (4,848.0) pt
Net income — 0 (7) (24) (37) (45) (102) (87) (75) (49) (53) n/m
Per share, $
Per share, $ Revenue — — 0.54 1.31 0.64 0.71 0.02 0.04 0.11 0.01 0.00 (40.4%)
Earnings — — (0.18) (3.17) (2.36) (1.07) (2.41) (2.05) (1.49) (0.70) (0.51) +21.4%
Cash flow — — (0.17) (2.78) (2.17) (1.36) (2.23) (1.91) (1.19) (0.57) (0.32) +19.4%
Capex — — 0.00 (0.06) (0.05) (0.19) (0.27) (0.01) 0.00 0.00 0.00 n/m
Free cash flow — — (0.17) (2.84) (2.22) (1.55) (2.50) (1.92) (1.19) (0.57) (0.32) +19.5%
Book value — — 0.91 1.92 19.98 6.47 4.16 3.40 1.57 1.18 1.63 +3.8%
Shares, m — — 42 8 16 42 42 43 51 70 96 +7.6%
Valuation, ×
Valuation, × P/E — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
P/S — — 14.36 14.36 81.81 11.92 3.45 194.36 10.74 45.31 106.26 47.0
P/B — — 0.00 0.00 2.62 1.32 0.60 2.23 0.77 3.08 2.82 1.3
EV/Sales — — 1.35 1.35 48.04 2.96 (1.80) 115.53 (2.02) 31.38 69.10 24.6
EV/FCF — — (0.51) (0.51) (13.88) (1.37) 0.52 (2.34) 0.19 (4.40) (9.39) (2.8)
Cash, $m
Cash, $m Operating cash flow — — (7) (21) (34) (57) (94) (81) (61) (40) (41) +28.5%
Capex — — (1) 0 (1) (8) (12) 0 0 0 0 (33.1%)
Free cash flow — — (7) (21) (34) (65) (106) (82) (61) (40) (41) +28.5%
Balance, $m
Balance, $m Working capital — — 45 22 329 264 160 132 70 75 206 +7.7%
Net debt — — (60) (39) (335) (269) (161) (131) (73) (78) (208) +3.7%
Shareholders’ equity — — 38 15 310 272 176 145 80 82 211 +11.7%
Returns, %
Returns, % ROA — — (21.68) (42.40) (18.58) (13.89) (40.46) (47.85) (60.18) (53.61) (36.88) (31.9) pt
ROIC — — 0.00 0.00 0.00 (948.80) (434.10) (408.19) (758.46) (744.34) (1,230.74) (744.3) pt
ROE — — 32.38 105.12 (26.59) (15.46) (45.52) (54.41) (67.23) (60.25) (39.21) (92.6) pt
People
People Employees — — — — 59 85 105 75 44 40 — (7.5%)
Revenue/emp, $m — — 0.00 0.00 0.17 0.35 0.01 0.02 0.13 0.03 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2025

Shattuck Labs, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
MDXG MiMedx Group, Inc $478.6M — (loss-making) — (loss-making) −45.23% (below 0%: shrinking) n/m −87.21% (below 0%: shrinking) 79.80% (18.79%) Compare
CTMX CytomX Therapeutics, Inc. $466.3M — (loss-making) — (loss-making) −71.69% (below 0%: shrinking) n/m +204.14% (above 0%: growing) 100.00% (1,392.30%) Compare
ETRA Electra Therapeutics Inc. $461.3M — — — — — — — Compare
MNPR Monopar Therapeutics Inc. $451.2M — (loss-making) — — n/m −201.41% (below 0%: shrinking) — 0.00% Compare
STTK Shattuck Labs, Inc. $450.6M — (loss-making) — (loss-making) −10.31% (below 0%: shrinking) n/m +1.01% (above 0%: growing) 100.00% 0.00%
EPRX Eupraxia Pharmaceuticals Inc. $429.1M — (loss-making) — — n/m −56.41% (below 0%: shrinking) — 0.00% Compare
ARVN Arvinas, Inc. $428.9M — (loss-making) — (loss-making) −98.81% (below 0%: shrinking) n/m +82.77% (above 0%: growing) 80.00% (11,820.00%) Compare
GYRE Gyre Therapeutics, Inc. $425.2M — (loss-making) — (loss-making) +7.75% (above 0%: growing) n/m −129.91% (below 0%: shrinking) 94.09% 0.00% Compare
PRTCY PureTech Health PLC Sponsored ADR $424.0M — (loss-making) — (loss-making) −44.60% (below 0%: shrinking) +66.43% (above 0%: growing) +19.27% (above 0%: growing) 2.83% 0.00% Compare
Median of peers $440.2M — — −45.23% — −56.41% 80.00% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 8 April 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 1.53m 3.35m 51.19
2024 3.22m 1.08m 16.97

Ownership

Directors and executive officers, together 8.79%
Entities affiliated with Prosight Management, LP 9.99%
Entities affiliated with Redmile Group, LLC 9.99%
Entities affiliated with Adage Capital Partners L.P. 9.99%
Entities affiliated with OrbiMed Advisors LLC 9.99%
T. Rowe Price Investment Management, Inc. 9.78%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Shattuck Labs, Inc. (STTK) Latest News

5 Nov

Impact 3 · · GlobeNewswire

13 Oct

Impact 3 · · GlobeNewswire

1 Oct

Impact 3 · · GlobeNewswire

11 Aug

Impact 3 ·

10 Jun

Impact 3 · · GlobeNewswire

9 Jun

Impact 3 · · GlobeNewswire

8 Jun

Impact 4 · · GlobeNewswire

5 Jun

Impact 3 · · GlobeNewswire

7 May

Impact 3 · · GlobeNewswire

1 May

Impact 3 · · Insider Monkey

6 Mar

Impact 4 · · The Motley Fool

5 Mar

Impact 3 · · GlobeNewswire

6 Feb

Impact 3 · · GlobeNewswire

5 Jan

Impact 4 · · The Motley Fool
Impact 4 · · Simply Wall St.

29 Nov

Impact 4 · · Insider MonkeyInsider MonkeyInsider MonkeyInsider MonkeyTipRanksInsider MonkeyInsider Monkey

6 Nov

Impact 3 · · GlobeNewswire

8 Oct

Impact 4 · · ZacksZacksZacksZacksZacksZacksZacksZacks

2 Oct

Impact 3 · · GlobeNewswire

19 Sep

Impact 3 ·

8 Sep

Impact 4 · · Zacks

4 Sep

Impact 4 · · Simply Wall St.

26 Aug

Impact 4 · · GlobeNewswire

21 Aug

Impact 4 ·
Impact 4 ·

14 Aug

Impact 4 · · GlobeNewswire

5 Aug

Impact 4 · · GlobeNewswire
Impact 3 ·

2 Jul

Impact 3 ·

13 Jun

Impact 3 ·
stockrow.com/STTK · Data as of Sep 30, 2025 · For information only; not investment advice. · © 2026 stockrow.com